Gene Expression Differences Predict Treatment Outcome of Merkel Cell Carcinoma Patients
Due to the rarity of Merkel cell carcinoma (MCC), prospective clinical trials have not been practical. This study aimed to identify biomarkers with prognostic significance. While sixty-two patients were identified who were treated for MCC at our institution, only seventeen patients had adequate form...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Journal of Skin Cancer |
| Online Access: | http://dx.doi.org/10.1155/2014/596459 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560990930075648 |
|---|---|
| author | Loren Masterson Bryan J. Thibodeau Laura E. Fortier Timothy J. Geddes Barbara L. Pruetz Rajwant Malhotra Richard Keidan George D. Wilson |
| author_facet | Loren Masterson Bryan J. Thibodeau Laura E. Fortier Timothy J. Geddes Barbara L. Pruetz Rajwant Malhotra Richard Keidan George D. Wilson |
| author_sort | Loren Masterson |
| collection | DOAJ |
| description | Due to the rarity of Merkel cell carcinoma (MCC), prospective clinical trials have not been practical. This study aimed to identify biomarkers with prognostic significance. While sixty-two patients were identified who were treated for MCC at our institution, only seventeen patients had adequate formalin-fixed paraffin-embedded archival tissue and followup to be included in the study. Patients were stratified into good, moderate, or poor prognosis. Laser capture microdissection was used to isolate tumor cells for subsequent RNA isolation and gene expression analysis with Affymetrix GeneChip Human Exon 1.0 ST arrays. Among the 191 genes demonstrating significant differential expression between prognostic groups, keratin 20 and neurofilament protein have previously been identified in studies of MCC and were significantly upregulated in tumors from patients with a poor prognosis. Immunohistochemistry further established that keratin 20 was overexpressed in the poor prognosis tumors. In addition, novel genes of interest such as phospholipase A2 group X, kinesin family member 3A, tumor protein D52, mucin 1, and KIT were upregulated in specimens from patients with poor prognosis. Our pilot study identified several gene expression differences which could be used in the future as prognostic biomarkers in MCC patients. |
| format | Article |
| id | doaj-art-02bf7c8438754024882bc31e9fe87750 |
| institution | Kabale University |
| issn | 2090-2905 2090-2913 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Skin Cancer |
| spelling | doaj-art-02bf7c8438754024882bc31e9fe877502025-02-03T01:26:13ZengWileyJournal of Skin Cancer2090-29052090-29132014-01-01201410.1155/2014/596459596459Gene Expression Differences Predict Treatment Outcome of Merkel Cell Carcinoma PatientsLoren Masterson0Bryan J. Thibodeau1Laura E. Fortier2Timothy J. Geddes3Barbara L. Pruetz4Rajwant Malhotra5Richard Keidan6George D. Wilson7Department of General Surgery, Beaumont Health System, Royal Oak, MI 48073, USADepartment of Beaumont BioBank, Beaumont Health System, 3811 West 13 Mile Road 105-RI, Royal Oak, MI 48073, USADepartment of Beaumont BioBank, Beaumont Health System, 3811 West 13 Mile Road 105-RI, Royal Oak, MI 48073, USADepartment of Beaumont BioBank, Beaumont Health System, 3811 West 13 Mile Road 105-RI, Royal Oak, MI 48073, USADepartment of Beaumont BioBank, Beaumont Health System, 3811 West 13 Mile Road 105-RI, Royal Oak, MI 48073, USADepartment of Anatomic Pathology, Beaumont Health System, Royal Oak, MI 48073, USADepartment of General Surgery, Beaumont Health System, Royal Oak, MI 48073, USADepartment of Beaumont BioBank, Beaumont Health System, 3811 West 13 Mile Road 105-RI, Royal Oak, MI 48073, USADue to the rarity of Merkel cell carcinoma (MCC), prospective clinical trials have not been practical. This study aimed to identify biomarkers with prognostic significance. While sixty-two patients were identified who were treated for MCC at our institution, only seventeen patients had adequate formalin-fixed paraffin-embedded archival tissue and followup to be included in the study. Patients were stratified into good, moderate, or poor prognosis. Laser capture microdissection was used to isolate tumor cells for subsequent RNA isolation and gene expression analysis with Affymetrix GeneChip Human Exon 1.0 ST arrays. Among the 191 genes demonstrating significant differential expression between prognostic groups, keratin 20 and neurofilament protein have previously been identified in studies of MCC and were significantly upregulated in tumors from patients with a poor prognosis. Immunohistochemistry further established that keratin 20 was overexpressed in the poor prognosis tumors. In addition, novel genes of interest such as phospholipase A2 group X, kinesin family member 3A, tumor protein D52, mucin 1, and KIT were upregulated in specimens from patients with poor prognosis. Our pilot study identified several gene expression differences which could be used in the future as prognostic biomarkers in MCC patients.http://dx.doi.org/10.1155/2014/596459 |
| spellingShingle | Loren Masterson Bryan J. Thibodeau Laura E. Fortier Timothy J. Geddes Barbara L. Pruetz Rajwant Malhotra Richard Keidan George D. Wilson Gene Expression Differences Predict Treatment Outcome of Merkel Cell Carcinoma Patients Journal of Skin Cancer |
| title | Gene Expression Differences Predict Treatment Outcome of Merkel Cell Carcinoma Patients |
| title_full | Gene Expression Differences Predict Treatment Outcome of Merkel Cell Carcinoma Patients |
| title_fullStr | Gene Expression Differences Predict Treatment Outcome of Merkel Cell Carcinoma Patients |
| title_full_unstemmed | Gene Expression Differences Predict Treatment Outcome of Merkel Cell Carcinoma Patients |
| title_short | Gene Expression Differences Predict Treatment Outcome of Merkel Cell Carcinoma Patients |
| title_sort | gene expression differences predict treatment outcome of merkel cell carcinoma patients |
| url | http://dx.doi.org/10.1155/2014/596459 |
| work_keys_str_mv | AT lorenmasterson geneexpressiondifferencespredicttreatmentoutcomeofmerkelcellcarcinomapatients AT bryanjthibodeau geneexpressiondifferencespredicttreatmentoutcomeofmerkelcellcarcinomapatients AT lauraefortier geneexpressiondifferencespredicttreatmentoutcomeofmerkelcellcarcinomapatients AT timothyjgeddes geneexpressiondifferencespredicttreatmentoutcomeofmerkelcellcarcinomapatients AT barbaralpruetz geneexpressiondifferencespredicttreatmentoutcomeofmerkelcellcarcinomapatients AT rajwantmalhotra geneexpressiondifferencespredicttreatmentoutcomeofmerkelcellcarcinomapatients AT richardkeidan geneexpressiondifferencespredicttreatmentoutcomeofmerkelcellcarcinomapatients AT georgedwilson geneexpressiondifferencespredicttreatmentoutcomeofmerkelcellcarcinomapatients |